Exabis Library
Welcome to the e-CCO Library!
P466: Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P466: Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P466: Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: a prospective single-centre open-label study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P466: Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P467 Can induction and maintenance serum vedolizumab levels predict long-term clinical outcome in inflammatory bowel disease (IBD)?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P467: 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn's disease - a nationwide cohort from the epi-IIRN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P467: A comparison of thiopurines vs. anti-TNF-α therapy in steroid-dependent ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P467: Circulating CD8 α4β7+ and CD8b7+ memory T cells as early biomarkers of clinical response to vedolizumab in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P467: Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P467: Perception Gap between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P467: The validation of the Crohn’s and Ulcerative Colitis Questionnaire–12 Plus (CUCQ-12 plus): a short quality-of-life measure for inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P467: Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P468: Analysis of international spontaneous reporting system databases for safety of corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and consequences of Corticosteroid Excess (DICE)-impact study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P468: Association of uncontrolled disease with quality of life and healthcare resource utilisation in Ulcerative Colitis patients treated with advanced therapy in the United States
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P468: Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology index
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P468: Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P468: Long-term efficacy and safety of thiopurine in biologic-naïve Japanese patients with ulcerative colitis: a multicentre retrospective study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P468: Long-term function after transanal vs. transabdominal ileal pouch-anal anastomosis for ulcerative colitis: a multi-centre cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P468: Microscopic colitis: systematic analysis of 200 adult patients with a mean follow-up of 4 years
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM